These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
473 related articles for article (PubMed ID: 23113654)
1. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME). Wiita AP; Nambiar A Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients. Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352 [TBL] [Abstract][Full Text] [Related]
3. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness]. Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359 [TBL] [Abstract][Full Text] [Related]
4. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840 [TBL] [Abstract][Full Text] [Related]
5. A comparison of volume-reduced versus standard HLA/HPA-matched apheresis platelets in alloimmunized adult patients. Honohan A; Tomson B; van der Bom J; de Vries R; Brand A Transfusion; 2012 Apr; 52(4):742-51. PubMed ID: 21981629 [TBL] [Abstract][Full Text] [Related]
6. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Gelb AB; Leavitt AD Transfusion; 1997 Jun; 37(6):624-30. PubMed ID: 9191823 [TBL] [Abstract][Full Text] [Related]
7. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients. Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026 [TBL] [Abstract][Full Text] [Related]
8. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347 [TBL] [Abstract][Full Text] [Related]
9. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG; Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Cameron B; Rock G; Olberg B; Neurath D Transfusion; 2007 Feb; 47(2):206-11. PubMed ID: 17302765 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376 [TBL] [Abstract][Full Text] [Related]
12. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. Bakchoul T; Bassler D; Heckmann M; Thiele T; Kiefel V; Gross I; Arnold DM; DiTomasso J; Smith JW; Paes B; Greinacher A Transfusion; 2014 Mar; 54(3):640-5. PubMed ID: 23869512 [TBL] [Abstract][Full Text] [Related]
13. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675 [TBL] [Abstract][Full Text] [Related]
14. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. Fontaine MJ; Kuo J; Chen G; Galel SA; Miller E; Sequeira F; Viele M; Goodnough LT; Tyan DB Transfusion; 2011 Dec; 51(12):2611-8. PubMed ID: 21615749 [TBL] [Abstract][Full Text] [Related]
15. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Rioux-Massé B; Cohn C; Lindgren B; Pulkrabek S; McCullough J Transfusion; 2014 Dec; 54(12):3080-7. PubMed ID: 24916382 [TBL] [Abstract][Full Text] [Related]
16. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients. Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968 [TBL] [Abstract][Full Text] [Related]